In an older MS population, several characteristics of immunosenescence might have impact on MS course and responses to treatments (Table 1). With aging, naïve T and B cells decline, with associated declines in the diversity of TCR and BCR repertoires [10]. Here, BCR is linked to myeloid sarcoma.